Ecallantide (Kalbitor)

Indications

  • Hereditary Angioedema (see Angioedema, [[Angioedema]])

Pharmacology

  • Plasma Kallikrein Inhibitor: decreases kallikrein-mediated synthesis of bradykinin

Metabolism

  • xxxx

Administration

  • SQ

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Allergic/Immunologic Adverse Effects

Anaphylaxis (see Anaphylaxis, [[Anaphylaxis]])

  • Epidemiology: occurs in 3% of cases
  • Clinical: usually occurs within 1 hr of administration

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx